

# Nishitha Reddy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5296048/publications.pdf>

Version: 2024-02-01

41  
papers

1,412  
citations

687363

13  
h-index

377865

34  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	28.9	804
2	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	2.5	115
3	Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 591-597.	2.0	82
4	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	1.4	59
5	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	7.1	44
6	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	1.6	37
7	Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 385-391.	0.4	35
8	A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. <i>Blood</i> , 2017, 130, 1676-1679.	1.4	26
9	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
10	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	23
11	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
12	Superior Long-Term Outcome of Patients With Early Transformation of Non-Hodgkin Lymphoma Undergoing Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 406-411.	0.4	19
13	Primary bone lymphoma: a set of unique problems in management. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-2.	1.3	16
14	Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3K $\gamma$ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies. <i>Blood</i> , 2018, 132, 2893-2893.	1.4	13
15	Treatment Options for Transformed Lymphoma: Incorporating Allogeneic Stem Cell Transplantation in a Multimodality Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1265-1272.	2.0	12
16	Hodgkin's Lymphoma: Richter's Transformation of Chronic Lymphocytic Leukemia Involving the Liver. <i>Journal of Clinical Oncology</i> , 2010, 28, e543-e544.	1.6	11
17	How we treat advanced stage cutaneous T-cell lymphoma "mycosis fungoides and S $\alpha$ zary syndrome. <i>British Journal of Haematology</i> , 2021, 195, 352-364.	2.5	10
18	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. <i>Experimental Hematology</i> , 2012, 40, 359-366.	0.4	8
20	Tolerability and durable responses of the PI3K inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2020, 38, 8016-8016.	1.6	8
21	Safety and Efficacy of Tenzalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. <i>Blood</i> , 2021, 138, 1365-1365.	1.4	8
22	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. <i>Blood</i> , 2019, 134, 19-19.	1.4	4
23	Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL. <i>Journal of Clinical Oncology</i> , 2022, 40, 7511-7511.	1.6	4
24	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	1.3	3
25	Efficacy and safety of the PI3K inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24). <i>Journal of Clinical Oncology</i> , 2021, 39, 7550-7550.	1.6	3
26	Safety of Mogamulizumab in Mycosis Fungoides and Sycophant Syndrome: Final Results from the Phase 3 Mavoric Study. <i>Blood</i> , 2019, 134, 5300-5300.	1.4	3
27	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	1.4	3
28	SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma. <i>Blood</i> , 2009, 114, 3733-3733.	1.4	2
29	Exploiting Tumor Necrosis Factor Aberrations in Marginal Zone Lymphoma. <i>JCO Precision Oncology</i> , 2021, 5, 569-573.	3.0	1
30	Initial results of the combination of PI3K inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 7553-7553.	1.6	1
31	MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 154-154.	1.4	1
32	Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study. <i>Blood</i> , 2019, 134, 2817-2817.	1.4	1
33	A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenzalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 8-10.	1.4	1
34	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
35	A High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Is Obesity a Risk Factor for APL? Implication of Targeted Therapy to Control Obesity and APL Prevention. <i>Blood</i> , 2009, 114, 3099-3099.	1.4	0
36	Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome. <i>Blood</i> , 2009, 114, 3407-3407.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019, 134, 1554-1554.	1.4	0
38	Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8043-8043.	1.6	0
39	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020, 136, 24-26.	1.4	0
40	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020, 136, 4-6.	1.4	0
41	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020, 136, 46-49.	1.4	0